Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
Distinguishing indolent from advanced systemic mastocytosis is notoriously complex, even for seasoned clinicians. To simplify diagnosis, researchers developed a mathematical model using basic lab values, achieving 93% predictive…
In this episode of the Oncology Brothers podcast hosted by Rohit Gosain, MD and Rahul Gosain, MD speak to Jorge Cortes, MD, from the Georgia Cancer Center, joins…
Hematologist-oncologist and author Vinay Prasad, MD, MPH, dismantles claims that ivermectin and fenbendazole are miracle cancer cures, while also criticizing the FDA’s approval process for expensive anti-cancer drugs…
Rohan Jotwani, MD, MBA, interventional pain specialist and anesthesiologist, Weill Cornell Medicine, and John Edwin Rubin, MD, assistant professor of clinical anesthesiology, Weill Cornell Medical College, Cornell University,…
Jen Gunter, MD, joins Mel Robbins to bust common myths about women’s health, from the truth about pubic hair and vaginal pH to the misinformation around cleanses, periods,…
Pompe disease is a rare, life-threatening genetic disorder caused by GAA enzyme deficiency, leading to glycogen buildup and muscle cell destruction. It presents on a spectrum, from infantile-onset…
Functional Neurological Disorder (FND) involves neurological symptoms arising from brain network changes rather than structural damage, often described as a “software” issue rather than a “hardware” problem. Symptoms…
